1,721,504 research outputs found
Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
No full textIntroduction: Multiple sclerosis (MS) is the most frequent cause of neurological impairment and sustained disability in young adults. Currently approved disease-modifying drugs do not directly ameliorate the most common symptoms, such as walking impairment. Dalfampridine (DAL), currently approved in all forms of MS, might represent an answer to unmet needs in the symptomatic treatment of MS. Areas covered: The main pharmacological and clinical properties and safety issues of DAL, an extended-release formulation of 4-aminopyridine (4-AP), a broad-spectrum voltage-dependent potassium channel blocker, are described. Relevant publications were identified from a search of PubMed from 1966 to June 2014 (search terms 'dalfampridine OR fampridine OR 4-aminopyridine). DAL, 10 mg twice daily, improves walking ability in approximately one-third and walking speed in about 25% of patients, independently from disease course, compared with placebo; it also improves leg strength. Treatment is generally well tolerated, although there is a dose-dependent increased risk of seizures, especially with dosages > 10 mg twice daily. Expert opinion: DAL represents an option in the symptomatic treatment of MS. Improved ambulation can impact quality of life, motivation and adherence, enhancing the successful management of MS. It has still to be established whether this favorably impacts costs associated with MS
RebiSmartTM (version 1.5) device for multiple sclerosis treatment delivery and adherence.
No full textIntroduction: First-line disease-modifying drugs for the treatment of multiple sclerosis (MS) are mostly administered by injection. Although these treatments can control the symptoms and progression of the disease to some extent, patients often fail to adhere to their therapy in the long term, so may not obtain the maximum clinical benefits. As injection-related problems are common barriers to adherence, autoinjectors have been developed to improve the ease and convenience of self-injection. Areas covered: This article discusses RebiSmart(TM), an electronic autoinjector for the subcutaneous administration of interferon β-1a, focusing on the device features and data from clinical trials of the device. An overview of other available autoinjectors for first-line MS therapies is provided for context. Expert opinion: The device is the first electronic autoinjector for use in MS and offers several innovative features, including adjustable injection settings and an electronic dosing log, which may improve adherence. The dosing log can be reviewed with the patient, allowing the physician to open a dialogue to discuss possible issues with treatment adherence. The use of multidose cartridges also provides a softer impact on the environment and easier disposal. The hidden needle helps avoid needle phobia and reduces the risk of needle stick injury
Ruolo degli anticorpi anti-gangliosidi nelle neuropatie e nelle malattie del motoneurone
No full textNeuropatie disimmuni: la terapia (presentato al 14° Corso di Aggiornamento della Società Italiana di Neurologia - Pisa)
No full textPathophysiology of weakness in MFS with anti-GQ1B antibodies: demyelinating, axonal, or something else?
No full text
Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor terminal block
No full text
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla
No full textQuesto volume nasce dall’esperienza di lavoro di alcuni Centri Sclerosi
Multipla. Esplora e ripercorre le fasi e i sintomi della malattia, propone i dati della letteratura recente
sull’efficacia a breve e a lungo termine dei vari farmaci ed il loro
utilizzo nelle diverse fasi della malattia. Infine, fornisce, una serie di consigli
pratici per la gestione degli effetti indesiderati locali nel sito di iniezione
e sistemici legati al trattamento.Tali suggerimenti, derivano dall’esperienza
quotidiana accumulata nel corso di oltre 10 anni e pertanto sono il frutto
di continue revisioni dell’esperienza maturata quotidianamente su
un’ampia casistica di soggetti affetti da tale malattia
- …
